Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Olaparib

FDA-approved product (capsule, oral), marketed as Lynparza.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Olaparib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • Neoplasm
  • Ovarian cancer
  • Ovarian carcinoma
  • Ovarian neoplasm
  • Pancreatic carcinoma
  • Pancreatic neoplasm
  • Prostate cancer
  • Prostate carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Poly (adp-ribose) polymerase (parp) inhibitors
FDA pharmacologic class
Poly(ADP-Ribose) Polymerase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA69.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli55.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae48.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Olaparib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Olaparib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • AMTEC IIT: Phase 2 Multiarm Study in TNBC

    NCT03801369 · start 2018-12-12

    Registered record
    Registry ID
    NCT03801369
    Conditions
    Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma
    Interventions
    Biopsy; Capivasertib; Ceralasertib; Durvalumab; Olaparib; Quality-of-Life Assessment; Selumetinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2018-12-12
    Completion
    2024-12-23
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma
    InterventionBiopsy; Capivasertib; Ceralasertib; Durvalumab +3 more
    PhasePhase 2
    Registry statusTerminated

  • Study to Evaluate CCS1477 in Advanced Tumours

    NCT03568656 · start 2018-07-23

    Registered record
    Registry ID
    NCT03568656
    Conditions
    Metastatic Castration-Resistant Prostate Cancer; Metastatic Breast Cancer; Non-small Cell Lung Cancer; Advanced Solid Tumors
    Interventions
    CCS1477; Abiraterone acetate; Enzalutamide; Darolutamide; Olaparib; Atezolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2018-07-23
    Completion
    2025-07-06
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration-Resistant Prostate Cancer; Metastatic Breast Cancer; Non-small Cell Lung Cancer; Advanced Solid Tumors
    InterventionCCS1477; Abiraterone acetate; Enzalutamide; Darolutamide +2 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)

    NCT03459846 · start 2018-03-16

    Registered record
    Registry ID
    NCT03459846
    Conditions
    Urinary Bladder Neoplasms
    Interventions
    Durvalumab; Olaparib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2018-03-16
    Completion
    2026-12-31
    Enrolment
    154

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Bladder Neoplasms
    InterventionDurvalumab; Olaparib; Placebo
    PhasePhase 2
    Registry statusActive not recruiting

  • Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC

    NCT02686008 · start 2018-01

    Registered record
    Registry ID
    NCT02686008
    Conditions
    Squamous Cell Carcinoma of the Head and Neck
    Interventions
    Olaparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2018-01
    Completion
    2019-07
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSquamous Cell Carcinoma of the Head and Neck
    InterventionOlaparib
    PhasePhase 1
    Registry statusWithdrawn

  • Selumetinib and Olaparib in Solid Tumors

    NCT03162627 · start 2017-08-04

    Registered record
    Registry ID
    NCT03162627
    Conditions
    Malignant Neoplasm of Breast; Malignant Neoplasms of Digestive Organs; Malignant Neoplasms of Female Genital Organs; Malignant Neoplasms of Male Genital Organs; Malignant Neoplasms of Thyroid and Other Endocrine Glands
    Interventions
    Selumetinib; Olaparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2017-08-04
    Completion
    2026-08-30
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Neoplasm of Breast; Malignant Neoplasms of Digestive Organs; Malignant Neoplasms of Female Genital Organs; Malignant Neoplasms of Male Genital Organs +1 more
    InterventionSelumetinib; Olaparib
    PhasePhase 1
    Registry statusActive not recruiting

  • Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib

    NCT03314740 · start 2017-06-12

    Registered record
    Registry ID
    NCT03314740
    Conditions
    Ovarian Neoplasms
    Interventions
    Paclitaxel; Cediranib; Olaparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-06-12
    Completion
    2021-04-01
    Enrolment
    123

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Neoplasms
    InterventionPaclitaxel; Cediranib; Olaparib
    PhasePhase 2
    Registry statusCompleted

  • Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

    NCT02345265 · start 2016-05-23

    Registered record
    Registry ID
    NCT02345265
    Conditions
    Fallopian Tube Carcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Ovarian Carcinoma; Ovarian High Grade Endometrioid Adenocarcinoma; Ovarian High Grade Serous Adenocarcinoma; Primary Peritoneal Carcinoma; Primary Peritoneal Endometrioid Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma
    Interventions
    Biopsy Procedure; Biospecimen Collection; Cediranib Maleate; Computed Tomography; Echocardiography Test; Magnetic Resonance Imaging; Multigated Acquisition Scan; Olaparib; Questionnaire Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2016-05-23
    Completion
    2027-03-04
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFallopian Tube Carcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Ovarian Carcinoma +5 more
    InterventionBiopsy Procedure; Biospecimen Collection; Cediranib Maleate; Computed Tomography +5 more
    PhasePhase 2
    Registry statusActive not recruiting

  • A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer

    NCT02561832 · start 2015-11-06

    Registered record
    Registry ID
    NCT02561832
    Conditions
    Breast Cancer
    Interventions
    Olaparib; Carboplatin; Anthracycline; Cyclophosphamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2015-11-06
    Completion
    2017-02-01
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionOlaparib; Carboplatin; Anthracycline; Cyclophosphamide
    PhasePhase 1
    Registry statusTerminated

  • Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

    NCT02282020 · start 2015-02-06

    Registered record
    Registry ID
    NCT02282020
    Conditions
    Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
    Interventions
    OLAPARIB; Single agent chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-02-06
    Completion
    2022-07-19
    Enrolment
    266

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
    InterventionOLAPARIB; Single agent chemotherapy
    PhasePhase 3
    Registry statusCompleted

  • Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

    NCT02184195 · start 2014-12-16

    Registered record
    Registry ID
    NCT02184195
    Conditions
    Germline BRCA1/2 Mutations and; Metastatic Adenocarcinoma of the Pancreas
    Interventions
    Olaparib; Olaparib; Placebo; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-12-16
    Completion
    2023-01-27
    Enrolment
    154

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGermline BRCA1/2 Mutations and; Metastatic Adenocarcinoma of the Pancreas
    InterventionOlaparib; Olaparib; Placebo; Placebo
    PhasePhase 3
    Registry statusCompleted

  • OSCA - Olaparib Standard of CAre Study

    NCT02262273 · start 2014-10

    Registered record
    Registry ID
    NCT02262273
    Conditions
    Platinum-sensitive Recurrent Serous Ovarian Cancer
    Interventions
    Data Collection
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-10
    Completion
    2016-04
    Enrolment
    2,123

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlatinum-sensitive Recurrent Serous Ovarian Cancer
    InterventionData Collection
    PhaseNot recorded
    Registry statusCompleted

  • Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment

    NCT02029001 · start 2014-03

    Registered record
    Registry ID
    NCT02029001
    Conditions
    Malignant Solid Neoplasms
    Interventions
    Nilotinib (400 mg BID); Everolimus (10 mg QD); Sorafenib (400 mg BID); Lapatinib (1500 mg QD); Pazopanib (800 mg QD); Olaparib (300 mg BID); Durvalumab + Tremelimumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2014-03
    Completion
    2028-10
    Enrolment
    900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Solid Neoplasms
    InterventionNilotinib (400 mg BID); Everolimus (10 mg QD); Sorafenib (400 mg BID); Lapatinib (1500 mg QD) +3 more
    PhasePhase 2
    Registry statusRecruiting

  • Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

    NCT01874353 · start 2013-09-03

    Registered record
    Registry ID
    NCT01874353
    Conditions
    Platinum Sensitive; BRCA Mutated; Relapsed Ovarian Cancer; Following Complete or Partial Response to Platinum Based Chemotherapy
    Interventions
    Olaparib 300mg tablets; Placebo to match olaparib 300mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2013-09-03
    Completion
    2026-12-31
    Enrolment
    327

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlatinum Sensitive; BRCA Mutated; Relapsed Ovarian Cancer; Following Complete or Partial Response to Platinum Based Chemotherapy
    InterventionOlaparib 300mg tablets; Placebo to match olaparib 300mg
    PhasePhase 3
    Registry statusActive not recruiting

  • D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid Tumours

    NCT01851265 · start 2013-07-04

    Registered record
    Registry ID
    NCT01851265
    Conditions
    Solid Tumours
    Interventions
    Olaparib; Dietary Fasted; Dietary standard; Dietary High Fat
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-07-04
    Completion
    2017-06-06
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumours
    InterventionOlaparib; Dietary Fasted; Dietary standard; Dietary High Fat
    PhasePhase 1
    Registry statusCompleted

  • Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History

    NCT01758731 · start 2012-10-22

    Registered record
    Registry ID
    NCT01758731
    Conditions
    Squamous Cell Carcinoma of the Head and Neck
    Interventions
    Olaparib; Cetuximab; Radiation Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-10-22
    Completion
    2018-10-31
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSquamous Cell Carcinoma of the Head and Neck
    InterventionOlaparib; Cetuximab; Radiation Therapy
    PhasePhase 1
    Registry statusCompleted